451 related articles for article (PubMed ID: 27760047)
1. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.
Paszkiewicz PJ; Fräßle SP; Srivastava S; Sommermeyer D; Hudecek M; Drexler I; Sadelain M; Liu L; Jensen MC; Riddell SR; Busch DH
J Clin Invest; 2016 Nov; 126(11):4262-4272. PubMed ID: 27760047
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
3. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
[TBL] [Abstract][Full Text] [Related]
4. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
[TBL] [Abstract][Full Text] [Related]
5. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
[TBL] [Abstract][Full Text] [Related]
6. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
[TBL] [Abstract][Full Text] [Related]
7. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
[TBL] [Abstract][Full Text] [Related]
8. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
Kochenderfer JN; Wilson WH; Janik JE; Dudley ME; Stetler-Stevenson M; Feldman SA; Maric I; Raffeld M; Nathan DA; Lanier BJ; Morgan RA; Rosenberg SA
Blood; 2010 Nov; 116(20):4099-102. PubMed ID: 20668228
[TBL] [Abstract][Full Text] [Related]
9. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
10. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
[TBL] [Abstract][Full Text] [Related]
12. A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
Lu TL; Pugach O; Somerville R; Rosenberg SA; Kochenderfer JN; Better M; Feldman SA
Hum Gene Ther Methods; 2016 Dec; 27(6):209-218. PubMed ID: 27897048
[TBL] [Abstract][Full Text] [Related]
13. CD19 chimeric antigen receptor T cell therapy for haematological malignancies.
Ghorashian S; Pule M; Amrolia P
Br J Haematol; 2015 May; 169(4):463-78. PubMed ID: 25753571
[TBL] [Abstract][Full Text] [Related]
14. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
15.
Pfeiffer A; Thalheimer FB; Hartmann S; Frank AM; Bender RR; Danisch S; Costa C; Wels WS; Modlich U; Stripecke R; Verhoeyen E; Buchholz CJ
EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224381
[TBL] [Abstract][Full Text] [Related]
16. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy.
Hill JA; Giralt S; Torgerson TR; Lazarus HM
Blood Rev; 2019 Nov; 38():100596. PubMed ID: 31416717
[TBL] [Abstract][Full Text] [Related]
17. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.
Turtle CJ; Riddell SR; Maloney DG
Clin Pharmacol Ther; 2016 Sep; 100(3):252-8. PubMed ID: 27170467
[TBL] [Abstract][Full Text] [Related]
18. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
Pennell CA; Barnum JL; McDonald-Hyman CS; Panoskaltsis-Mortari A; Riddle MJ; Xiong Z; Loschi M; Thangavelu G; Campbell HM; Storlie MD; Refaeli Y; Furlan SN; Jensen MC; Kean LS; Miller JS; Tolar J; Osborn MJ; Blazar BR
Mol Ther; 2018 Jun; 26(6):1423-1434. PubMed ID: 29735365
[TBL] [Abstract][Full Text] [Related]
19. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
Chen R; Song XT; Chen B
Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
[TBL] [Abstract][Full Text] [Related]
20. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
